Eleven names new CFO and chair of board
This article was originally published in Scrip
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company developing therapies for eye diseases, has appointed Gregory D Perry chief financial and business officer and Daniel S Lynch as chair of its board of directors. Eleven has also named Koltan Pharmaceuticals' senior vice-president and chief business officer Jane Pritchett Henderson as a member of its board.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.